Pasar al contenido principal

CARACTERIZACION DEL EJE TEJIDO ADIPOSO-HIGADO EN LA ENFERMEDAD HEPATICA POR HIGADO GRASO NO ALCOHOLICO. MACROFAGOS INFILTRANTES DEL TEJIDO ADIPOSO COMO DIANA TERAPEUTICA.

PI18/00862

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2018
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PRIVADA CLINIC
Centro realización HOSPITAL CLINICO Y PROVINCIAL DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Therapeutic targeting of adipose tissue macrophages ameliorates liver fibrosis in non-alcoholic fatty liver disease

  • Martínez-Sánchez, Celia
  • Bassegoda, Octavi|||0000-0002-6036-6026
  • Deng, Hongping
  • Almodóvar, Xènia
  • Ibarzabal, Ainitze|||0000-0002-1220-6474
  • de Hollanda, Ana|||0000-0001-9114-8614
  • Martínez García de la Torre, Raquel-Adela
  • Blaya, Delia
  • Ariño, Silvia
  • Jiménez-Esquivel, Natalia
  • Aguilar-Bravo, Beatriz
  • Vallverdú, Julia
  • Montironi, Carla|||0000-0002-1453-2193
  • Osorio-Conles, Oscar
  • Fundora Suarez, Yiliam|||0000-0003-4950-6988
  • Sánchez Moreno, Francisco Javier
  • Gómez-Valadés, Alicia G.
  • Aguilar-Corominas, Laia
  • Soria, Anna|||0000-0001-5671-8343
  • Pose, Elisa|||0000-0002-0224-7686
  • Juanola, Adrià|||0000-0003-4832-5130
  • Cervera, Marta
  • Perez, Martina
  • Hernández-Gea, Virginia|||0000-0001-7937-984X
  • Affò, Silvia
  • Swanson, Kelly S.
  • Ferrer-Fàbrega, Joana
  • Balibrea Del Castillo, José María|||0000-0002-0764-7179
  • Sancho-Bru, Pau|||0000-0001-5569-9259
  • Vidal, Josep|||0000-0002-4564-4518
  • Ginès, Pere|||0000-0003-4657-4504
  • Smith, Andrew M.
  • Graupera, Isabel|||0000-0001-9170-9784
  • Coll, Mar|||0000-0003-3726-0087
: The accumulation of adipose tissue macrophages (ATMs) in obesity has been associated with hepatic injury. However, the contribution of ATMs to hepatic fibrosis in non-alcoholic fatty liver disease (NAFLD) remains to be elucidated. Herein, we investigate the relationship between ATMs and liver fibrosis in patients with patients with NAFLD and evaluate the impact of modulation of ATMs over hepatic fibrosis in an experimental non-alcoholic steatohepatitis (NASH) model. Adipose tissue and liver biopsies from 42 patients with NAFLD with different fibrosis stages were collected. ATMs were characterised by immunohistochemistry and flow cytometry and the correlation between ATMs and liver fibrosis stages was assessed. Selective modulation of the ATM phenotype was achieved by i.p. administration of dextran coupled with dexamethasone in diet-induced obesity and NASH murine models. Chronic administration effects were evaluated by histology and gene expression analysis in adipose tissue and liver samples. In vitro crosstalk between human ATMs and hepatic stellate cells (HSCs) and liver spheroids was performed. Patients with NAFLD presented an increased accumulation of pro-inflammatory ATMs that correlated with hepatic fibrosis. Long-term modulation of ATMs significantly reduced pro-inflammatory phenotype and ameliorated adipose tissue inflammation. Moreover, ATMs modulation was associated with an improvement in steatosis and hepatic inflammation and significantly reduced fibrosis progression in an experimental NASH model. In vitro, the reduction of the pro-inflammatory phenotype of human ATMs with dextran-dexamethasone treatment reduced the secretion of inflammatory chemokines and directly attenuated the pro-fibrogenic response in HSCs and liver spheroids. Pro-inflammatory ATMs increase in parallel with fibrosis degree in patients with NAFLD and their modulation in an experimental NASH model improves liver fibrosis, uncovering the potential of ATMs as a therapeutic target to mitigate liver fibrosis in NAFLD. We report that human adipose tissue pro-inflammatory macrophages correlate with hepatic fibrosis in non-alcoholic fatty liver disease (NAFLD). Furthermore, the modulation of adipose tissue macrophages (ATMs) by dextran-nanocarrier conjugated with dexamethasone shifts the pro-inflammatory phenotype of ATMs to an anti-inflammatory phenotype in an experimental murine model of non-alcoholic steatohepatitis. This shift ameliorates adipose tissue inflammation, hepatic inflammation, and fibrosis. Our results highlight the relevance of adipose tissue in NAFLD pathophysiology and unveil ATMs as a potential target for NAFLD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

High frequency of acute decompensation and cancer in patients with compensated cirrhosis due to nonalcoholic fatty liver disease, A retrospective cohort study

  • Bassegoda, Octavi|||0000-0002-6036-6026
  • Rivera Esteban, Jesús|||0000-0003-4357-8817
  • Serra Matamala, Isabel|||0000-0002-5694-9325
  • Morillas Cunill, Rosa Ma|||0000-0001-9117-5049
  • Broquetas, Teresa|||0000-0002-5935-3076
  • Vergara, Mercedes|||0000-0002-6971-8657
  • Rodriguez Castellano, Adrià|||0000-0001-6548-0269
  • Aracil, Carlos|||0000-0002-8228-9041
  • Virolés, Silvia
  • Carrión Rodríguez, José Antonio|||0000-0001-7191-6081
  • Pardo, Albert|||0000-0002-3159-6762
  • Rodríguez-Tajes, Sergio|||0000-0002-3189-7557
  • Serra-Burriel, Miquel
  • Pericàs, Juan M.|||0000-0002-3645-3293
  • Augustin Recio, Salvador|||0000-0002-3515-9033
  • Ginès, Pere|||0000-0003-4657-4504
  • Graupera, Isabel|||0000-0001-9170-9784
The natural history of compensated cirrhosis due to nonalcoholic fatty liver disease (NAFLD) has not been completely characterized. The aim of the present study was to assess the incidence and risk factors of acute decompensation of cirrhosis, hepatocellular carcinoma, and extrahepatic cancers. This was a multicenter, retrospective, cohort study including 449 patients with compensated cirrhosis due to NAFLD. We calculated cumulative incidences and used competitive risk analysis to determine the risk factors associated with decompensation and cancer development. Over a median of 39 months of follow-up, 124 patients (28%) presented acute decompensation. The most frequent decompensation was ascites (21%) followed by hepatic encephalopathy (15%), variceal bleeding (9%), and spontaneous bacterial peritonitis (3%). Acute-on-chronic liver failure was diagnosed in 6% of patients during follow-up. Liver function parameters and specifically an albumin level below 40 g/L were independently associated with an increased risk of decompensation. The presence of ischemic heart disease was independently associated with acute decompensation. Seventy-eight patients (18%) developed hepatocellular carcinoma or extrahepatic cancers during follow-up (51 and 27, respectively). Conclusion : Patients with compensated cirrhosis due to NAFLD are at high risk of severe liver complications, such as the development of acute decompensation, in a relative short follow-up time. This population is at high risk of hepatic and extrahepatic cancers. The analysis of a large contemporary cohort of 449 patients with compensated cirrhosis due to non-alcoholic fatty liver disease shows a high frequency of acute decompensations (AD) and development of cancer during 39 months of follow-up. Almost 28% of the cohort developed acute decompensation and 18% developed hepatocellular carcinoma (HCC) or extrahepatic cancer. Predictors of decompensation are mainly related to liver function and portal hypertension.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

LiverScreen project, study protocol for screening for liver fibrosis in the general population in European countries

  • Graupera, Isabel|||0000-0001-9170-9784
  • Thiele, Maja
  • Ma, Ann T.|||0000-0002-9059-111X
  • Serra-Burriel, Miquel
  • Pich, Judit
  • Fabrellas, Núria|||0000-0001-6720-0291
  • Caballería, Llorenç|||0000-0002-7990-0719
  • de Knegt, Robert J.
  • Grgurevic, Ivica
  • Reichert, Mathias
  • Roulot, Dominique
  • Schattenberg, Jörn M.
  • Pericàs, Juan M.|||0000-0002-3645-3293
  • Angeli, Paolo|||0000-0002-1913-0716
  • Tsochatzis, Emmanuel A.
  • Guha, Indra Neil
  • Garcia-Retortillo, M.|||0000-0001-6783-7604
  • Morillas Cunill, Rosa Ma|||0000-0001-9117-5049
  • Hernández, Rosario
  • Hoyo, Jordi
  • Fuentes, Matilde
  • Madir, Anita
  • Juanola, Adrià|||0000-0003-4832-5130
  • Soria, Anna|||0000-0001-5671-8343
  • Juan, Marta
  • Carol, Marta
  • Díaz, Alba|||0000-0002-0456-7085
  • Detlefsen, Sönke
  • Torán-Monserrat, Pere|||0000-0002-9865-7427
  • Fournier, Céline
  • Llorca, Anne
  • Newsome, Phillip N.
  • Manns, Michael|||0000-0002-4485-8856
  • de Koning, Harry J.
  • Serra-Burriel, Feliu
  • Cucchietti, Fernando|||0000-0002-9027-1263
  • Arslanow, Anita
  • Korenjak, Marko|||0000-0003-4024-677X
  • van Kleef, Laurens
  • Falcó, Josep Lluis
  • Kamath, P.S.|||0000-0002-7888-1165
  • Karlsen, Tom H.
  • Castera, Laurent
  • Lammert, Frank
  • Krag, Aleksander|||0000-0002-9598-4932
  • Ginès, Pere|||0000-0003-4657-4504
The development of liver cirrhosis is usually an asymptomatic process until late stages when complications occur. The potential reversibility of the disease is dependent on early diagnosis of liver fibrosis and timely targeted treatment. Recently, the use of non-invasive tools has been suggested for screening of liver fibrosis, especially in subjects with risk factors for chronic liver disease. Nevertheless, large population-based studies with cost-effectiveness analyses are still lacking to support the widespread use of such tools. The aim of this study is to investigate whether non-invasive liver stiffness measurement in the general population is useful to identify subjects with asymptomatic, advanced chronic liver disease. This study aims to include 30,000 subjects from eight European countries. Subjects from the general population aged ≥ 40 years without known liver disease will be invited to participate in the study either through phone calls/letters or through their primary care center. In the first study visit, subjects will undergo bloodwork as well as hepatic fat quantification and liver stiffness measurement (LSM) by vibration-controlled transient elastography. If LSM is ≥ 8 kPa and/or if ALT levels are ≥1.5 x upper limit of normal, subjects will be referred to hospital for further evaluation and consideration of liver biopsy. The primary outcome is the percentage of subjects with LSM ≥ 8kPa. In addition, a health economic evaluation will be performed to assess the cost-effectiveness and budget impact of such an intervention. The project is funded by the European Commission H2020 program. This study comes at an especially important time, as the burden of chronic liver diseases is expected to increase in the coming years. There is consequently an urgent need to change our current approach, from diagnosing the disease late when the impact of interventions may be limited to diagnosing the disease earlier, when the patient is asymptomatic and free of complications, and the disease potentially reversible. Ultimately, the LiverScreen study will serve as a basis from which diagnostic pathways can be developed and adapted to the specific socio-economic and healthcare conditions in each country. This study is registered on (). The online version contains supplementary material available at 10.1186/s12889-022-13724-6.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Correction, LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries

  • Graupera, Isabel|||0000-0001-9170-9784
  • Thiele, Maja
  • Ma, Ann T.|||0000-0002-9059-111X
  • Serra-Burriel, Miquel
  • Pich, Judit
  • Fabrellas, Núria|||0000-0001-6720-0291
  • Caballería, Llorenç|||0000-0002-7990-0719
  • de Knegt, Robert J.
  • Grgurevic, Ivica
  • Reichert, Mathias
  • Roulot, Dominique
  • Schattenberg, Jörn M.
  • Pericàs, Juan M.|||0000-0002-3645-3293
  • Angeli, Paolo|||0000-0002-1913-0716
  • Tsochatzis, Emmanuel A.
  • Guha, Indra Neil
  • Garcia-Retortillo, M.|||0000-0001-6783-7604
  • Morillas Cunill, Rosa Ma|||0000-0001-9117-5049
  • Hernández, Rosario
  • Hoyo, Jordi
  • Fuentes, Matilde
  • Madir, Anita
  • Juanola, Adrià|||0000-0003-4832-5130
  • Soria, Anna|||0000-0001-5671-8343
  • Juan, Marta
  • Carol, Marta
  • Díaz, Alba|||0000-0002-0456-7085
  • Detlefsen, Sönke
  • Torán-Monserrat, Pere|||0000-0002-9865-7427
  • Pera, Guillem|||0000-0003-3188-7268
  • Fournier, Céline
  • Llorca, Anne
  • Newsome, Phillip N.
  • Manns, Michael|||0000-0002-4485-8856
  • de Koning, Harry J.
  • Serra-Burriel, Feliu
  • Cucchietti, Fernando|||0000-0002-9027-1263
  • Arslanow, Anita
  • Korenjak, Marko|||0000-0003-4024-677X
  • van Kleef, Laurens
  • Falcó, Josep Lluis
  • Kamath, P.S.|||0000-0002-7888-1165
  • Karlsen, Tom H.
  • Castera, Laurent
  • Lammert, Frank
  • Krag, Aleksander|||0000-0002-9598-4932
  • Ginès, Pere|||0000-0003-4657-4504